Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pryma, Daniel A., Chin, Bennett B., Noto, Richard B., Dillon, Joseph S., Perkins, Stephanie, Solnes, Lilja, Kostakoglu, Lale, Serafini, Aldo N., Pampaloni, Miguel H., Jensen, Jessica, Armor, Thomas, Lin, Tess, White, Theresa, Stambler, Nancy, Apfel, Stuart, DiPippo, Vincent A., Mahmood, Syed, Wong, Vivien, Jimenez, Camilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2019
Materias:
Theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://www.ncbi.nlm.nih.gov/pubmed/30291194
http://dx.doi.org/10.2967/jnumed.118.217463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://www.ncbi.nlm.nih.gov/pubmed/30291194
http://dx.doi.org/10.2967/jnumed.118.217463

Ejemplares similares